Article
Association of CYP2C19*2 polymorphism with clopidogrel response and 1-year major adverse cardiovascular events in a multiethnic population with drug-eluting stents.
Pharmacogenomics - 1 Aug 2017
Tan Shirley Siang Ning, Fong Alan Yean Yip, Mejin Melissa, Gerunsin Jerry, Kong Khai Liy, Chin Felicia Yien Yin, Tiong Lee Len, Lim Melissa Siaw Han, Asri Said, Khiew Ning Zan, Voon Chi Yen, Mohd Amin Nor Hanim, Cham Yee Ling, Koh Keng Tat, Oon Yen Yee, Ong Tiong Kiam
Abstract excerpt
BACKGROUND: Patients undergoing elective percutaneous coronary intervention (PCI) with drug-eluting stents (DES) who have impaired clopidogrel response, have a higher risk of subsequent major adverse cardiovascular events (MACE). AIM OF THE STUDY: To establish the relationship between CYP2C19 genotype, clopidogrel responsiveness and 1-year MACE. MATERIALS & METHODS: Aspirin/clopidogrel responses were assessed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.